The European Circular Bioeconomy Fund has announced its final closing at €300m, €50m above its target.
TargED Biopharmaceuticals will use €39m from a Series A financing to bring its thrombolytic treatment to patients.
The cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.